The immunological era in melanoma treatment: New challenges for heat shock protein-based vaccine in the advanced disease

Expert Opinion on Biological Therapy

Volumn 11, Issue 10, 2011, Pages 1395-1407

  Di Pietro, Alessandra ^a   Tosti, Giulio ^a   Ferrucci, Pier Francesco ^a   Testori, Alessandro ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Gp96; Heat shock protein peptide complex; Heat shock proteins; HSP; HSPC4; HSPPC; HSPPC 96; Immunotherapy; Melanoma; Oncophage; Prophage; Vaccine; Vitespen

Indexed keywords

ALPHA2B INTERFERON; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; HEAT SHOCK PROTEIN; INTERLEUKIN 2; IPILIMUMAB; PEGINTERFERON ALPHA2B; TICILIMUMAB; TUMOR VACCINE; UNCLASSIFIED DRUG; VITESPEN; YERVOY;

ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHILL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FATIGUE; HEADACHE; HUMAN; INJECTION SITE REACTION; KIDNEY CANCER; MELANOMA; MYALGIA; NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SIDE EFFECT;

ANIMALS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HEAT-SHOCK PROTEINS; HUMANS; MELANOMA; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 80052438963     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.605353     Document Type: Article

References (107)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010;60:277-300
2. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206
3. Balch C, Kirkwood J, Reintgen DS. Cutaneous melanoma. In: Devita VT. editor. Cancer: principles and practice in oncology. 5th edition. Lippincott; Philadelphia: 1997. p. 1947-94
4. Parmiani G, Castelli C, Santinami M, Rivoltini L. Melanoma immunology: past, present and future. Curr Opin Oncol 2007;19:121-7 (Pubitemid 46204351)
5. Kawakami Y, Wang X, Shofuda T, et al. Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes. J Immunol 2001;166:2871-7 (Pubitemid 32173530)
6. Rivoltini L, Castelli C, Carrabba M, et al. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T-cells. J Immunol 2003;171:3467-74 (Pubitemid 37254548)
7. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009;100:2014-21
8. Terando AM, Faries MB, Morton DL. Vaccine therapy for melanoma: current status and future directions. Vaccine 2007;25(Suppl 2):B4-B16 (Pubitemid 47488552)
9. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004;40:1825-36 (Pubitemid 39036756)
10. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16 (Pubitemid 29318842)
11. Kirkwood JM, Ernstoff M. Melanoma: therapeutic options with recombinant interferons. Semin Oncol 1985;12:7-12 (Pubitemid 16184752)
12. Kirkwood JM, Ernstoff MS, Davis CA, et al. Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med 1985;103:32-6 (Pubitemid 15068495)
13. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/ C9190. J Clin Oncol 2000;18:2444-58 (Pubitemid 30415832)
14. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/ C509801. J Clin Oncol 2001;19:2370-80 (Pubitemid 32391207)
15. Available from: www.accessdata.fda.gov/ drugsatfda-docs/label/2011/ 103949s5153lbl.pdf (Last accessed 25 July 2011)
16. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008;372:117-26 (Pubitemid 351952257)
17. Agarwala SS, Ferri W, Gooding W, Kirkwood JM. A Phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer 1999;85:1979-84 (Pubitemid 29202773)
18. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17:2745-51 (Pubitemid 29415231)
19. Atkins MB, Lee S, Flaherty LE, et al. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol 2003;22. 708
20. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999;17:968-75 (Pubitemid 29109330)
21. Ridolfi R, Chiarion-Sileni V, Guida M, et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alfa-2b in advanced melanoma outpatients: results from an Italian multicenter Phase III randomized clinical trial. J Clin Oncol 2002;20:1600-7 (Pubitemid 34260541)
22. Keilholz U, Punt CJ, Gore M, et al. Dacarbazine, cisplatin and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized Phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005;23:6747-55 (Pubitemid 46190270)
23. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a Phase III randomized trial. J Clin Oncol 2002;20:2045-52 (Pubitemid 34408794)
24. Atkins MB, Hsu J, Lee S, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2 and interferon alfa-2b with cisplatin, vinblastine and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the eastern Cooperative Oncology Group. J Clin Oncol 2008;26:5748-54
25. Gehrmann M. Drug evaluation: STA-4783 - enhancing taxane efficacy by induction of Hsp70. Curr Opin Investig Drugs 2006;7:574-80 (Pubitemid 43891037)
26. Teft WA, Kirchhof MG, Madrenas JA. Molecular perspective of CTLA-4 function. Ann Rev Immunol 2006;24:65-97
27. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a Phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005;23:8968-77 (Pubitemid 46217464)
28. Ribas A, Antonia S, Sosman J, et al. Results of a Phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma [abstract 3000]. J Clin Oncol 2007;25(18S):118
29. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23:6043-53
30. Weber JS, O'Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008;26:5950-6
31. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26
32. Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte associated antigen 4 blockade and interleukin 2: a Phase I/II study. Ann Surg Oncol 2005;12:1005-16 (Pubitemid 41660676)
33. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a Phase I trial of a fully human anti cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005;23:741-50 (Pubitemid 46224173)
34. Schadendorf D, Wolchok J, Neyns B, et al. Activity of ipilimumab at 10mg/kg in patients with advanced melanoma is independent of baseline prognostic factors [abstract 9308]. Eur J Cancer Suppl 2009;7(3):579
35. Hodi FS, O'Day S, McDermott DF, et al. Improved survival with Ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
36. Butte M, Keir M, Phamuduy T, et al. Programmed death-1 ligand interacts specifically with the B7-1 costimulatory molecules to inhibit T cell responses. Immunity 2007;27:111-22 (Pubitemid 47089023)
37. Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7:95-106 (Pubitemid 46160986)
38. Sznol M, Hodi FS, Margolin K, et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). ASCO Meeting Abstracts. J Clin Oncol 2008;26:abstract 3007
39. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a Phase II randomized discontinuation trial analysis. Br J Cancer 2006;95:581-6 (Pubitemid 44325897)
40. Morabito A, De Maio E, Di Maio M, et al. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006;11:753-64 (Pubitemid 44157563)
41. End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001;61:131-7 (Pubitemid 32095710)
42. Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26:2139-46
43. Margolin K, Longmate J, Baratta T, et al. CCI-779 in metastatic melanoma: a Phase II trial of the California Cancer Consortium. Cancer 2005;104:1045-8 (Pubitemid 41170233)
44. Eggermont AMM. Advances in systemic treatment of melanoma. Ann Oncol 2010;21:339-44
45. Hanna MG Jr, Peters LC. Specific immunotherapy of established visceral micrometastases by BCG-tumor cell vaccine alone or as an adjunct to surgery. Cancer 1978;42:2613-25 (Pubitemid 9095032)
46. Key ME, Brandhorst JS, Hanna MG Jr. Synergistic effects of active specific immunotherapy and chemotherapy in guinea pigs with disseminated cancer. J Immunol 1983;130:2987-92 (Pubitemid 13107744)
47. Peters LC, Brandhorst JS, Hanna MG Jr. Preparation of immunotherapeutic autologous tumor cell vaccines from solid tumors. Cancer Res 1979;39:1353-60 (Pubitemid 9183856)
48. Fang L, Lonsdorf AS, Hwang ST. Immunotherapy for advanced melanoma. J Invest Dermatol 2008;128:2596-605
49. + progenitor-derived dendritic cell vaccine. Cancer Res 2001;61:6451-8 (Pubitemid 32783251)
50. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32 (Pubitemid 28144092)
51. Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006;17:563-70
52. Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669-78 (Pubitemid 30002348)
53. Bedikian AY, Del Vecchio M. Allovectin-7 therapy in metastatic melanoma. Expert Opin Biol Ther 2008;8:839-44 (Pubitemid 351860213)
54. Galanis E. Technology evaluation: Allovectin-7, Vical. Curr Opin Mol Ther 2002;4:80-7
55. Bolhassani A, Rafati S. Heat-shock proteins as powerful weapons in vaccine development. Expert Rev Vaccines 2008;7:1185-99
56. Alexandrescu DT, Ichim TE, Riordan NH, et al. Immunotherapy for melanoma: current status and perspectives. J Immunother 2010;33:570-90
57. Kampinga HH, Hageman J, Vos MJ, et al. Guidelines for the nomenclature of the human heat shock proteins. Cell Stress Chaperones 2009;14:105-11
58. Udono H, Srivastava PK. Comparison of tumor specific immunogenicities of stress-induced proteins gp96, hsp90 and hsp70. J Immunol 1994;152:5398-403 (Pubitemid 24152988)
59. Oki Y, Younes A. Heat shock protein-based cancer vaccines. Expert Rev Vaccines 2004;3:403-11 (Pubitemid 39061705)
60. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein chaperoned peptides. Science 1995;269:1585-8
61. Castelli C, Ciupitu AM, Rini F, et al. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res 2001;61:222-7 (Pubitemid 32095721)
62. Srivastava PK. Interaction of heat shock proteins with peptides and antigen presenting cells: Chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 2002;20:395-425
63. Srivastava PK. Immunotherapy for human cancer using heat shock protein-peptide complexes. Curr Oncol Rep 2005;7:104-8 (Pubitemid 40485465)
64. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70 and calreticulin. Immunity 2001;14:303-13 (Pubitemid 32289294)
65. Binder RJ, Srivastava PK. Essential role of CD91 in re-presentation of gp96-chaperoned peptides. Proc Natl Acad Sci USA 2004;101:6128-33 (Pubitemid 38520539)
66. Binder RJ, Han DK, Srivastava PK. CD91: a receptor for heat shock protein gp96. Nat Immunol 2000;1:151-5
67. Matsutake T, Sawamura T, Srivastava PK. High efficiency CD91- and LOX-1-mediated re-presentation of gp96-chaperoned peptides by MHC II molecules. Cancer Immun 2010;10:7. Available from: . cancerimmunity.org/v10p7/100606.htm
68. Vabulas RM, Ahmad-Nejad P, Ghose S, et al. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem 2002;277:15107-12 (Pubitemid 34952589)
69. Asea A, Kraeft SK, Kurt-Jones EA, et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000;6:435-42 (Pubitemid 30208161)
70. Panjwani NN, Popova L, Srivastava PK. Heat shock proteins gp96 and hsp70 activate the release of nitric oxide by APCs. J Immunol 2002;168:2997-3003 (Pubitemid 34211681)
71. Lehner T, Bergmeier LA, Wang Y, et al. Heat shock proteins generate beta-chemokines which function as innate adjuvants enhancing adaptive immunity. Eur J Immunol 2000;30:594-603 (Pubitemid 30098853)
72. Basu S, Binder RJ, Suto R, et al. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappaB pathway. Int Immunol 2000;12:1539-46
73. Elsner L, Muppala V, Gehrmann M, et al. The heat shock protein HSP70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands. J Immunol 2007;179:5523-33
74. Pilla L, Squarcina P, Coppa J, et al. Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96. Cancer Res 2005;65:3942-9 (Pubitemid 40616377)
75. Udono H, Levey DL, Srivastava PK. Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc Natl Acad Sci USA 1994;91:3077-81 (Pubitemid 24130178)
76. Kumaraguru U, Gierynska M, Norman S, et al. Immunization with chaperone-peptide complex induces low-avidity cytotoxic T lymphocytes providing transient protection against herpes simplex virus infection. J Virol 2002;76:136-41 (Pubitemid 33138999)
77. Manjili MH, Henderson R, Wang XY, et al. Development of a recombinant HSP110-HER-2/neu vaccine using the chaperoning properties of HSP110. Cancer Res 2002;62:1737-42 (Pubitemid 34408496)
78. Hoos A, Levey DL. Vaccination with heat shock protein- peptide complexes: from basic science to clinical applications. Expert Rev Vaccines 2003;2:369-79 (Pubitemid 36713363)
79. Gordon NF, Clark BL. The challenges of bringing autologous HSP-based vaccines to commercial reality. Methods 2004;32:63-9 (Pubitemid 37421182)
80. Zabrecky JR, Sawlivich W. Purification of the heat shock protein, gp96, from natural sources. Methods 2004;32:3-6 (Pubitemid 37424021)
81. Eton O, Ross MI, East MJ, et al. Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. J Transl Med 2010;8:9
82. Available from: www.agenusbio.com/ prophage/prophage.html [Last accessed 6 April 2011]
83. Pilla L, Patuzzo R, Rivoltini L, et al. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother 2006;55:958-68 (Pubitemid 43673585)
84. Testori A, Richards J, Whitman E, et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol 2008;26:955-62 (Pubitemid 351398090)
85. Bouwhuis MG, ten Hagen TL, Eggermont AM. Immunologic functions as prognostic indicators in melanoma. Mol Oncol 2011;5:183-9
86. Younes A, Fayad LE, Pro B. Safety and efficacy of heat shock protein-peptide 96 complex (HSPPC-96) in low grade lymphoma. Proc Am Soc Clin Oncol (ASCO) 2003;22:2294
87. Mazzaferro V, Coppa J, Carrabba MG, et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 2003;9:3235-45 (Pubitemid 37082717)
88. Li Z. Autologous leucocyte-derived heat shock protein 70-peptide complex as a vaccine for chronic myelogenous leukemia in chronic phase: an updated phase I. Blood 2003;102:11
89. Younes A. A Phase II study of heat shock proteinpeptide complex-96 vaccinetherapy in patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma 2003;4:183-5 (Pubitemid 38128684)
90. Oki Y, McLaughlin P, Fayad LE, et al. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer 2007;109:77-83 (Pubitemid 46120196)
91. Belli F, Testori A, Rivoltini L, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 2002;20:4169-80 (Pubitemid 35191019)
92. Eton O. Autologous tumor-derived heat-shock-protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. Proc Am Assoc Cancer Res (AACR) 2000;41
93. Heike M. Pilot trial of vaccination with autologous tumour-derived Gp-96 Heat Shock Protein Peptide Complex (HSPPC-96) in patients after surgery for gastric carcinoma. Proc Am Soc Clin Oncol (ASCO) 2000;41:3463
94. Hertkorn C, Lehr A, Woelfel T, et al. Phase I trial of vaccination with autologous-tumor derived gp96 (oncophage) in patients after surgery for gastric cancer. Proc Am Soc Clin Oncol (ASCO) 2002;21:117
95. Parsa A, Crane C, Wilson S et al. Autologous tumor derived gp96 evokes a tumor specific immune response in recurrent glioma patients that correlates with clinical response to therapy. AACR-NCI-EORTC 2007. International Conference Molecular Targets and Cancer Therapeutics 2007, abstract C274
96. Jonasch E, Wood C, Tamboli P, et al. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer 2008;98:1336-41 (Pubitemid 351543568)
97. Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008;372:145-54
98. Wood CG, Srivastava P, Lacombe L, et al. Survival update from multicenter, randomized, phase III trial of vitespen versus observation as adjuvant therapy for renal cell carcinoma in patients at high risk of recurrence. J Clin Oncol 2009;15S:abstract #3009
99. Maki E, Livingston PO, Lewis JJ, et al. A Phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci 2007;52:1964-72 (Pubitemid 47024649)
100. Dong J, Wei J. Effective vaccines of autologous cancer-derived heat shock protein gp70-complexes in patients with cancer malignancies (pancreatic carcinoma, colo-rectal cancer). Proc Am Soc Clin Oncol (ASCO) 2005;23;2591
101. Li Z, Nash JD, Qiao Y, et al. An autologous tumor derived heat shock protein vaccine for high risk ovarian cancer. Proc Am Soc Clin Onc (ASCO) 2005;23:9592
102. Di Pietro A, Tosti G, Ferrucci PF, Testori A. Oncophage: step to the future for vaccine therapy in melanoma. Exp Opin Biol Ther 2008;8:1973-84
103. Singh-Jasuja H, Scherer HU, Hilf N, et al. The heat shock protein gp96 induces maturation of dendritic cells and downregulation of its receptor. Eur J Immunol 2000;30:2211-15 (Pubitemid 30655760)
104. Srivastava PK. Immunotherapy of human cancer: lessons from mice. Nat Immunol 2000;1:363-6
105. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006;24:4738-45 (Pubitemid 46630937)
106. Schicher N, Paulitschke V, Swoboda A, et al. Erlotinib and bevacizumab have synergistic activity against melanoma. Clin Cancer Res 2009;15:3495-502
107. Parsa A, Aghi M, Ahn B, et al. Autologous heat shock protein vaccine for patients with newly diagnosed and recurrent glioblastoma [abstract IX-2]. The 18th International Conference on Brain Tumor Research and Therapy; Travemunde, Germany; 2010